What is NovoCure's G&A?

NovoCure (NVCR) reported G&A of $85.85M in Q1 2026.

How has NovoCure's G&A changed year-over-year?

NovoCure's G&A increased by 91.8% year-over-year, from $44.77M to $85.85M.

What is the long-term trend for NovoCure's G&A?

Over 4 years (2021 to 2025), NovoCure's G&A has grown at a 8.9% compound annual growth rate (CAGR), from $126.13M to $177.67M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

NovoCure NVCR G&A

G&A at other companies

Iovance Biotherapeutics, Inc.IOVA

$38.95M-11.1%

Syndax PharmaceuticalsSNDX

$37.59M-8.4%

ArriVent BioPharma, Inc.AVBP

$8.49M+54.9%

Tyra Biosciences, Inc.TYRA

$8.53M+23.8%

Immunovant, Inc.IMVT

$17.27M-14.4%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's G&A?: NovoCure (NVCR) reported G&A of $85.85M in Q1 2026.
How has NovoCure's G&A changed year-over-year?: NovoCure's G&A increased by 91.8% year-over-year, from $44.77M to $85.85M.
What is the long-term trend for NovoCure's G&A?: Over 4 years (2021 to 2025), NovoCure's G&A has grown at a 8.9% compound annual growth rate (CAGR), from $126.13M to $177.67M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.